These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35508865)

  • 1. PLK4 inhibitor plus bortezomib exhibits a synergistic effect on treating multiple myeloma via inactivating PI3K/AKT signaling.
    Xu B; Li J; Xu D; Ran Q
    Ir J Med Sci; 2023 Apr; 192(2):561-567. PubMed ID: 35508865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STMN1 promotes cell malignancy and bortezomib resistance of multiple myeloma cell lines via PI3K/AKT signaling.
    Wang L; Cao J; Tao J; Liang Y
    Expert Opin Drug Saf; 2024 Mar; 23(3):277-286. PubMed ID: 37642368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fraxetin down-regulates polo-like kinase 4 (PLK4) to inhibit proliferation, migration and invasion of prostate cancer cells through the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) pathway.
    Ma Z; Sun Y; Peng W
    Bioengineered; 2022 Apr; 13(4):9345-9356. PubMed ID: 35387563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PLK4 inhibitor exhibits antitumor effect and synergizes sorafenib via arresting cell cycle and inactivating Wnt/β-catenin pathway in anaplastic thyroid cancer.
    Zhu W; Xie B
    Cancer Biol Ther; 2023 Dec; 24(1):2223383. PubMed ID: 37351847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of the phosphoinostitide-3'-kinase delta inhibitor, CAL-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism].
    Qu F; Xia B; Li X; Guo S; Zhang L; Tian C; Yu Y; Zhang Y
    Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):412-7. PubMed ID: 26463142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of PLK4 might enhance the anti-tumour effect of bortezomib on glioblastoma via PTEN/PI3K/AKT/mTOR signalling pathway.
    Wang J; Ren D; Sun Y; Xu C; Wang C; Cheng R; Wang L; Jia G; Ren J; Ma J; Tu Y; Ji H
    J Cell Mol Med; 2020 Apr; 24(7):3931-3947. PubMed ID: 32126150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential combination of bortezomib and WEE1 inhibitor, MK-1775, induced apoptosis in multiple myeloma cell lines.
    Barbosa RSS; Dantonio PM; Guimarães T; de Oliveira MB; Fook Alves VL; Sandes AF; Fernando RC; Colleoni GWB
    Biochem Biophys Res Commun; 2019 Nov; 519(3):597-604. PubMed ID: 31540690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.
    Que W; Chen J; Chuang M; Jiang D
    APMIS; 2012 Mar; 120(3):195-203. PubMed ID: 22339676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diallyl thiosulfinate enhanced the anti-cancer activity of dexamethasone in the side population cells of multiple myeloma by promoting miR-127-3p and deactivating the PI3K/AKT signaling pathway.
    He W; Fu Y; Zheng Y; Wang X; Liu B; Zeng J
    BMC Cancer; 2021 Feb; 21(1):125. PubMed ID: 33549034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel phosphatidylinositol 3-kinase inhibitor BKM120 enhances the sensitivity of multiple myeloma to bortezomib and overcomes resistance.
    Yu W; Chen Y; Xiang R; Xu W; Wang Y; Tong J; Zhang N; Wu Y; Yan H
    Leuk Lymphoma; 2017 Feb; 58(2):428-437. PubMed ID: 27439454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silybin suppresses cell proliferation and induces apoptosis of multiple myeloma cells via the PI3K/Akt/mTOR signaling pathway.
    Feng N; Luo J; Guo X
    Mol Med Rep; 2016 Apr; 13(4):3243-8. PubMed ID: 26936429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib.
    Malek E; Driscoll JJ
    Oncotarget; 2016 Jun; 7(25):38523-38538. PubMed ID: 27229530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-451 regulates stemness of side population cells via PI3K/Akt/mTOR signaling pathway in multiple myeloma.
    Du J; Liu S; He J; Liu X; Qu Y; Yan W; Fan J; Li R; Xi H; Fu W; Zhang C; Yang J; Hou J
    Oncotarget; 2015 Jun; 6(17):14993-5007. PubMed ID: 25915427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of TRIM31 Gene Silencing on the Proliferation and Apoptosis of U266 Cells and Its Mechanism].
    Long XX; Wen F; Chen Q; Cao YX; Huang XQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Jun; 29(3):805-811. PubMed ID: 34105476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formononetin Regulates Multiple Oncogenic Signaling Cascades and Enhances Sensitivity to Bortezomib in a Multiple Myeloma Mouse Model.
    Kim C; Lee JH; Ko JH; Chinnathambi A; Alharbi SA; Shair OHM; Sethi G; Ahn KS
    Biomolecules; 2019 Jul; 9(7):. PubMed ID: 31284669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus shows synergistic antimyeloma effects with bortezomib via the AKT/mTOR pathway.
    Li J; Liu Z; Li Y; Jing Q; Wang H; Liu H; Chen J; Feng J; Shao Q; Fu R
    J Investig Med; 2019 Jan; 67(1):39-47. PubMed ID: 29997148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity.
    Zhang HR; Chen JM; Zeng ZY; Que WZ
    J Int Med Res; 2013 Jun; 41(3):584-95. PubMed ID: 23613505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of PSMB5 on proliferation and bortezomib chemo-resistance in human myeloma cells and its related molecular mechanisms].
    Mo HM; Wu QY; Han DY; Liu R; Ma X; Zhou P; Xu KL
    Zhonghua Xue Ye Xue Za Zhi; 2017 Dec; 38(12):1053-1057. PubMed ID: 29365400
    [No Abstract]   [Full Text] [Related]  

  • 19. miR-215-5p is an anticancer gene in multiple myeloma by targeting RUNX1 and deactivating the PI3K/AKT/mTOR pathway.
    Liu S; Zhang Y; Huang C; Lin S
    J Cell Biochem; 2020 Feb; 121(2):1475-1490. PubMed ID: 31498483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyrroline-5-Carboxylate Reductase 1: a novel target for sensitizing multiple myeloma cells to bortezomib by inhibition of PRAS40-mediated protein synthesis.
    Oudaert I; Satilmis H; Vlummens P; De Brouwer W; Maes A; Hose D; De Bruyne E; Ghesquière B; Vanderkerken K; De Veirman K; Menu E
    J Exp Clin Cancer Res; 2022 Feb; 41(1):45. PubMed ID: 35105345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.